Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Open Label Multi-center Study to Compare Immunogenicity and Safety of BBV154 With COVAXIN®, and to Assess Lot to Lot Consistency of BBV154 in Healthy Volunteers

NCT05522335 is registered in ClinicalTrials.gov with Bharat Biotech International Limited as lead sponsor.

NCT NCT05522335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05522335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Open Label Multi-center Study to Compare Immunogenicity and Safety of BBV154 With COVAXIN®, and to Assess Lot to Lot Consistency of BBV154 in Healthy Volunteers
Lead sponsor
Bharat Biotech International Limited
Phase
Phase 3
Overall status
Unknown status
Start date
April 16, 2022
Completion date
February 28, 2023
Enrollment
3,160 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 respiratory infection